Key result
Oral L-arginine supplementation (up to 9 g daily) for 12 weeks did not improve absolute claudication distance compared to control in 80 patients with peripheral arterial disease.
Why the study?
Does oral L-arginine supplementation improve absolute claudication distance in patients with peripheral arterial disease and intermittent claudication?
RCT (n=80)
Randomly assigned
Does oral L-arginine supplementation improve absolute claudication distance in patients with peripheral arterial disease and intermittent claudication?
In a pilot study of patients with PAD, oral L-arginine supplementation for 12 weeks did not significantly improve absolute claudication distance compared to control.
Answers are grounded in this paper and cite their sources.
L-arginine offers no benefit for claudication distance in PAD; this RCT does not support its use and challenges prior assumptions of efficacy.
Peripheral arterial disease (PAD) impairs walking capacity and is often associated with a profound endothelial vasodilator dysfunction, characterized by reduced bioactivity and/or synthesis of endothelium-derived nitric oxide (NO). Previous studies have suggested that dietary supplementation of L-arginine, the precursor of NO, improves endothelium-dependent vasodilation, limb blood flow and walking distance. However, these studies have been small, and have used large intravenous doses of L-arginine. The optimal dose of L-arginine has not been determined. Accordingly, this pilot study was conducted to establish the lowest effective oral dose of L-arginine to improve walking distance in preparation for the definitive study. Patients with PAD and intermittent claudication (n = 80) participated in this study. Eligibility criteria included: (1) ankle-brachial index (ABI) at rest < or = 0.90; (2) post-exercise reduction in ABI > or = 25%; and (3) difference in absolute claudication distance of < or = 25% between two consecutive treadmill tests. Treadmill testing was performed using the Skinner-Gardner protocol and community-based walking was assessed using the walking impairment questionnaire. Patients were randomly assigned to oral doses of 0, 3, 6 or 9 g of L-arginine daily in three divided doses for 12 weeks. Treadmill testing was performed prior to administration of the study drug and again after 12 weeks of treatment. The study drug was well tolerated, with no significant adverse effects of L-arginine therapy. The safety laboratory studies were unremarkable, except for a statistically significant reduction in hematocrit in the L-arginine-treated groups. There was no significant difference observed in absolute claudication distance between the groups. However, a trend was observed for a greater increase in walking distance in the group treated with 3 g L-arginine daily, and there was a trend for an improvement in walking speed in patients treated with L-arginine. This pilot study provided data for safety, for power calculation and for dosing for the larger definitive trial that is now underway.
No takes yet. Share an insight, caveat, or question.
Oka et al. (2005) conducted an RCT in Peripheral arterial disease and intermittent claudication (n=80). L-arginine vs. 0 g daily was evaluated on Absolute claudication distance. Oral L-arginine supplementation (up to 9 g daily) for 12 weeks did not improve absolute claudication distance compared to control in 80 patients with peripheral arterial disease.
Synapse has enriched 10 related papers. Consider them for comparative context: